P1.11-28 Lung Cancer: Susceptibility and Survival Differences for Women and Men

Yip, Rowena; Fevrier, E.; Wolf, Andrea; Triphuridet, Natthaya; Henschke, Claudia I.

doi:10.1016/j.jtho.2019.08.1101

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors have previously shown that women are at higher risk to develop lung cancer than equally smoking men (13)(14)(15)(16). When the probability of lung cancer among I-ELCAP smokers with sex, age, pack-years of smoking and years since quit was modeled a 55-year-old man with at least 30 pack-years of smoking would have about the same risk as a 47 year-old woman with the same smoking history (17).…”

Section: Introductionmentioning

confidence: 99%

Review of the future of lung cancer screening

Yip¹,

Jirapatnakul²,

Li³

et al. 2022

Curr Chall Thorac Surg

View full text Add to dashboard Cite

Lung cancer screening has progressed greatly in the last two decades since the initial publication of ELCAP in 1999. Since then, large randomized trials, the NLST and NELSON studies, have also shown the benefit of lung cancer screening with CT, and it is now widely available. There are many areas for improving the benefit of screening by refining the eligibility criteria, continued optimization of the screening regimen, identifying other related diseases, and improved treatment. As artificial intelligence (AI) techniques continue to improve, an automated report of all diseases can be produced from the low-dose CT scan. New screening tests are being developed for lung cancer including blood-based tests. There is growing recognition that use of risk factor-based criteria which dichotomize age and pack-years of smoking to select eligible individuals for screening may not be the most efficient and may also lead to increased lung cancer disparity. Continued research will focus on optimal approaches for selecting high risk individuals for lung cancer screening and thus hopefully expand eligibility criteria beyond the current criteria which include only 20% of lung cancer patients. With the increase in early stage lung cancers identified from lung cancer screening, a key focus of ongoing research is the treatment of these cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Review of the future of lung cancer screening

Yip¹,

Jirapatnakul²,

Li³

et al. 2022

Curr Chall Thorac Surg

View full text Add to dashboard Cite

show abstract

The Regimen of Computed Tomography Screening for Lung Cancer

Henschke

Yip

Shaham

et al. 2020

Journal of Thoracic Imaging

View full text Add to dashboard Cite

We learned many unanticipated and valuable lessons since we started planning our study of low-dose computed tomography (CT) screening for lung cancer in 1991. The publication of the baseline results of the Early Lung Cancer Action Project (ELCAP) in Lancet 1999 showed that CT screening could identify a high proportion of early, curable lung cancers. This stimulated large national screening studies to be quickly started. The ELCAP design, which provided evidence about screening in the context of a clinical program, was able to rapidly expand to a 12-institution study in New York State (NY-ELCAP) and to many international institutions (International-ELCAP), ultimately working with 82 institutions, all using the common I-ELCAP protocol. This expansion was possible because the investigators had developed the ELCAP Management System for screening, capturing data and CT images, and providing for quality assurance. This advanced registry and its rapid accumulation of data and images allowed continual assessment and updating of the regimen of screening as advances in knowledge and new technology emerged. For example, in the initial ELCAP study, introduction of helical CT scanners had allowed imaging of the entire lungs in a single breath, but the images were obtained in 10 mm increments resulting in about 30 images per person. Today, images are obtained in submillimeter slice thickness, resulting in around 700 images per person, which are viewed on high-resolution monitors. The regimen provides the imaging acquisition parameters, imaging interpretation, definition of positive result, and the recommendations for further workup, which now include identification of emphysema and coronary artery calcifications. Continual updating is critical to maximize the benefit of screening and to minimize potential harms. Insights were gained about the natural history of lung cancers, identification and management of nodule subtypes, increased understanding of nodule imaging and pathologic features, and measurement variability inherent in CT scanners. The registry also provides the foundation for assessment of new statistical techniques, including artificial intelligence, and integration of effective genomic and blood-based biomarkers, as they are developed.

show abstract

P1.11-28 Lung Cancer: Susceptibility and Survival Differences for Women and Men

Cited by 2 publications

References 0 publications

Review of the future of lung cancer screening

Review of the future of lung cancer screening

The Regimen of Computed Tomography Screening for Lung Cancer

Contact Info

Product

Resources

About